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Inhibition of glutamate 
decarboxylase (GAD) by ethyl 
ketopentenoate (EKP) induces 
treatment-resistant epileptic 
seizures in zebrafish
Yifan Zhang  1, Michiel Vanmeert2, Aleksandra Siekierska1, Annelii Ny1, Jubi John3,6, Geert 
Callewaert  4, Eveline Lescrinier2, Wim Dehaen3, Peter A. M. de Witte1 & Rafal M. Kaminski  5
Epilepsy is a chronic brain disorder characterized by recurrent seizures due to abnormal, excessive and 
synchronous neuronal activities in the brain. It affects approximately 65 million people worldwide, 
one third of which are still estimated to suffer from refractory seizures. Glutamic acid decarboxylase 
(GAD) that converts glutamate into GABA is a key enzyme in the dynamic regulation of neural 
network excitability. Importantly, clinical evidence shows that lowered GAD activity is associated with 
several forms of epilepsy which are often treatment resistant. In the present study, we synthetized 
and explored the possibility of using ethyl ketopentenoate (EKP), a lipid-permeable GAD-inhibitor, 
to induce refractory seizures in zebrafish larvae. Our results demonstrate that EKP evoked robust 
convulsive locomotor activities, excessive epileptiform discharges and upregulated c-fos expression in 
zebrafish. Moreover, transgenic animals in which neuronal cells express apoaequorin, a Ca2+-sensitive 
bioluminescent photoprotein, displayed large luminescence signals indicating strong EKP-induced 
neuronal activation. Molecular docking data indicated that this proconvulsant activity resulted from 
the direct inhibition of both gad67 and gad65. Limited protective efficacy of tested anti-seizure drugs 
(ASDs) demonstrated a high level of treatment resistance of EKP-induced seizures. We conclude that 
the EKP zebrafish model can serve as a high-throughput platform for novel ASDs discovery.
Epilepsies are complex neurological disorders characterized by recurrent, unprovoked seizures resulting from 
the imbalance between excitatory and inhibitory neuronal processes occurring in the brain1. Despite the current 
therapeutic regimens and the availability of more than 20 anti-seizure drugs (ASDs), seizures are still poorly con-
trolled in a significant proportion of patients (ca. 20–30%)2. Hence, there is a need for the generation of new in 
vivo models with the appropriate pathological background, to speed up the discovery of novel hits active against 
drug-resistant epilepsies3, 4.
Although traditional gatekeeper models like the maximal electroshock seizure and subcutaneous (s.c.) pen-
tylenetetrazole (PTZ) seizure test have been instrumental for preclinical discovery of ASDs, these models may 
fail to identify novel compounds with improved efficacy against drug-resistant epilepsies4. ILEA defines drug 
resistant epilepsy as failure of two adequate trials of tolerated and appropriately chosen ASDs5. Consequently, an 
animal model can be considered as “drug resistant” if seizures do not respond (or respond poorly) to treatment 
with at least two current ASDs at maximum tolerated doses4. A number of promising rodent models which fulfill 
this definition have been developed over recent years6. Such models can be broadly categorized as those that rely 
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on selection of ASD non-responders or those in which animals exhibit a poor drug response and in such case the 
models are “per se” resistant to ASDs3, 4. While some of these models are tunable to medium-throughput drug 
screens (e.g. the 6 Hz (44 mA) acute seizure model), most models (i.e. selection of non-responder animals in kin-
dling or post status epilepticus models) are however difficult to implement because of their relatively high costs 
and labor-intensive procedures.
Zebrafish have received a great deal of attention over the last decade as a cost-efficient and relevant alternative 
for human disease modelling and large-scale drug screenings7–9. Besides ease of handling and fast reproduction 
rate, zebrafish share high genetic, cellular and organ homologies to humans10. Consequently, over recent years 
several chemical and genetic zebrafish models of acute seizures or epilepsy have been generated either by immer-
sion of larvae in chemical proconvulsants like PTZ11, 12 or D-AG13, or by knocking down or introducing mutations 
in epilepsy susceptible genes including lgi114, scn1Lab15, 16, and kcnq317.
Gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system 
(CNS), counterbalances neuronal excitability and hence plays a vital role in the predisposition/treatment of epilepsy18. 
Consequently, a substantial number of ASDs target the GABAergic system to suppress seizures through enhanc-
ing GABA-mediated inhibition (benzodiazepines, and barbiturates), inhibiting GABA catabolism (valproate and 
vigabatrin) or preventing GABA reuptake (tiagabine). Conversely, chemicals like PTZ, bicuculline, penicillin and 
picrotoxin that antagonize the GABAergic pathway can cause seizures13, 19.
GABA is bio-synthesized through oxidative decarboxylation of glutamate (Glu) catalyzed by the rate-limiting 
enzyme glutamate decarboxylase (GAD, EC 4.1.1.15). In mammals, GAD exists in two isoforms, GAD67 and 
GAD6518, 20 encoded by the GAD1 and GAD2 genes, respectively. Although both isoforms are co-expressed in 
GABAergic neurons, their expression levels and subcellular localization differ, and hence they likely play different 
roles in GABA-mediated neurotransmission21. Gad65−/− mice are spared from major morphological defects and 
display no significant changes in brain GABA content, but these animals develop spontaneous seizures associated 
with increased mortality22 and show enhanced seizure susceptibility to picrotoxin and PTZ23. Gad67−/− mice, on 
the other hand, show a 93% reduction in GABA concentration in the cerebral cortex. As these animals exhibit 
severe cleft palate resulting in neonatal death, their epileptic phenotype remains largely unknown24. gad1b and 
gad2 are the zebrafish orthologues of human GAD1 and GAD2 and share around 76% homology. The encoded 
proteins gad67 and gad65 have been identified in brain and spinal cord tissue of developing zebrafish embryos 
and mediate local GABA synthesis25, 26. The zebrafish genome also includes a gad3 gene that is considered as an 
ancient paralog of GAD1 and GAD2 that is lost in the hominid and rodent lineages. However, no specific role of 
gad3 could be identified27.
Clinical evidence further shows that lowered GAD activity is associated with several forms of epilepsy. 
Reduced GAD activity has been found in epileptic foci from patients with intractable epilepsy, indicating 
that failure to synthesize GABA and loss of inhibitory synaptic activity may lead to epilepsy28. Furthermore, 
in autoimmune epilepsies, GAD antibodies have been detected especially in patients with focal epilepsies like 
drug-resistant temporal lobe epilepsy (TLE)29–34.
These data underscore the validity of decreasing GAD activity in zebrafish as an epilepsy-relevant paradigm 
for drug discovery. (D, L)-allylglycine (AG, 2-amino-4-pentenoic acid) is a GAD inhibitor that induces epileptic 
convulsions and neuronal damage in rodents and goldfish, and decreases the threshold for photic-induced sei-
zures in baboons with photosensitive epilepsy35–37.
Recently, Leclercq et al. compared AG-induced acute seizures in zebrafish larvae and adult mice. The results 
showed clear cross-species similarities with regard to seizure behavior and demonstrated limited efficacy 
of ASDs13. A drawback of the AG zebrafish model is that seizures occurred asynchronously and with a long 
latency to onset. This is likely due to sluggish and highly variable uptake of this strongly hydrophilic compound 
(clogP = −2.18). At high AG concentrations (range 200 mM − 300 mM) latency onset was reduced but seizures 
continued to progress and became lethal. Thus, although the concept of GAD inhibition is attractive and relevant, 
AG administration in zebrafish is accompanied with practical issues that limit its applicability as a model for drug 
screening.
In vitro studies have shown that AG is a weak inhibitor of GAD with a Ki value of about 50 mM. Conversely, 
2-keto-4-pentenoic acid (KPA), the in vivo occurring deaminated metabolite of AG, has a much stronger inhibi-
tory effect with a Ki of 10−6 M. Moreover, in mice, ED50 values for seizure induction after intracerebroventricular 
(icv) administration is 14.5 µg/kg for KPA compared to 375 µg/kg for L-AG and 804 µg/kg for D-AG, respectively37.
Therefore, in this study, we synthesized ethyl ketopentenoate (EKP), a lipophilic ethyl ester of KPA, and tested 
its ability to induce seizures in 7 days post-fertilization (dpf) zebrafish larvae. Epileptiform activity was detected 
by locomotor tracking, local field potential and neuroluminescence recordings. For the latter, a novel assay was set 
up based on a transgenic luminescent zebrafish line. In addition, commercially available ASDs were evaluated for 
their ability to inhibit EKP-induced hyperactivity. We conclude that EKP is more effective than AG in inducing 
refractory seizures and could serve as a high-throughput model for the discovery of novel ASDs.
Results
gad expression during zebrafish development. qPCR showed that both gad1b and gad2 were expressed 
in zebrafish larvae between 1 dpf and 7 dpf (Fig. 1). Expression was low at 1 dpf, then significantly increased dur-
ing the first 3 days of development (p ≤ 0.05) to remain constant at later stages (4–7 dpf, p > 0.05).
Validation of larval zebrafish EKP seizure model. Locomotion activity and survival rate. Zebrafish 
larvae at 7 dpf were exposed to various concentrations of EKP (200 μM-800 μM) to identify an optimal working 
concentration for induction of seizure-like activities. Locomotor activities of both VHC- and EKP-treated larvae 
were monitored and quantified by an automated video-based behavioral tracking system.
www.nature.com/scientificreports/
3Scientific RepoRts | 7: 7195  | DOI:10.1038/s41598-017-06294-w
VHC-treated larvae swam infrequently in a small dart-like manner and displayed baseline activities. Larvae 
exposed to EKP exhibited increased activity compared to VHC group in general with three different phases of 
seizure-related locomotion (Fig. 2A, statistical analysis see Table S2).
A first phase was characterized by an increasing number of bursts of hyperactivity and agitation. At EKP con-
centrations ≥300 μM this was followed by a second phase in which hyperactivity reached a plateau. At this point 
larvae also tended to swim more rapidly in a corkscrew-like manner accompanied with entire body jerking and 
twitching. In a third phase, the period of increased motility was followed by an irreversible decline of the total 
larval movement at concentrations between 300–800 μM. This was due to loss of body posture and paralysis (as 
observed under a microscope), and finally larval death (Fig. 2A). Onset and duration of each phase were clearly 
dose-dependent. As 400 μM EKP induced a robust increase of locomotor activity without inducing any larval 
death during the first 30 min (Fig. 2B,C), this concentration was used for further validation and pharmacological 
characterization of the model.
Local field potential (LFP) recordings and c-fos expression. In order to confirm that 400 μM EKP-treated zebrafish 
larvae displayed abnormal brain activity, LFP recordings were performed in the optic tectum of both VHC- and 
EKP-treated 7 dpf larvae. 7 out of 35 VHC-treated larvae showed some epileptiform-like activity while multi-
ple epileptiform events were found in all EKP-treated larvae (58/58) (Fig. 3A,B). In EKP-treated animals the 
mean frequency was 55.76 ± 6.87 events/10 min versus 0.48 ± 0.18 events/10 min in VHC-treated ones (Fig. 3B). 
Similarly to PTZ treated animals, c-fos expression was significantly increased in EKP-treated larvae compared to 
VHC-treated ones (Fig. 3C).
Neuroluminescence recordings. Next, neuronal activity was assayed in freely behaving zebrafish using the lumi-
nescent approach as reported by Naumann et al.38. Transgenic zebrafish Tg(elavl3:eGFP-apoAequorin(GA))expre
ssing GFP-apoAequorin under the control of the elavl3 promoter were generated (Fig. 4A) and neuroluminescent 
signals were recorded for 30 min in VHC- and EKP-treated animals. In the VHC-treated group the averaged 
aequorin light signal remained relatively stable throughout the experiment. In EKP-treated larvae the averaged 
light signal was increased and displayed large fluctuations over time (Fig. 4B), resembling the LFP recordings 
in the same group. Hence, in vivo neuroluminescence clearly allows to detect and study abnormal brain activity 
occurring in freely behaving animals.
Figure 1. Developmental gad1b and gad2 expression by qPCR. Gene expression levels were quantified relative 
to reference gene elongation factor 1 alpha (elfα), and 18s ribosomal RNA (18s) expression by ΔΔCq method. 
Zebrafish larvae samples from 1–7 dpf are shown. Results for each gene are expressed as mean ± s.e.m. of 
three experiments performed in triplicate. p-values calculated using Student’s unpaired t-test (*p ≤ 0.05). (A) 
Developmental expression of gad1b. (B) Developmental expression of gad2.
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Pharmacology activity. Next, 14 commercially available ASDs were evaluated for their ability to prevent 
EKP-induced epileptiform activity. Larvae were pre-incubated for 18 hours (h) with the indicated ASD at its 
maximum tolerated concentration (MTC). Epileptiform activity was scored with behavior tracking, LFP and 
neuroluminescence recordings.
In case of behavior tracking, an ASD was considered to be active or slightly active if at least two time points 
or only one time point, respectively, showed a statistically significant decline in total movement in comparison 
with the EKP control group (Fig. S2)11. Based on these criteria, perampanel (PER) and zonisamide (ZSM) were 
identified as active compounds with PER as the only ASD that significantly prevented EKP-induced locomotion. 
Phenytoin (PHT) and topiramate (TPM) were identified as slightly active compounds (Fig. 5A).
LFP recordings revealed that ZSM, PER and TMP significantly attenuated the number of epileptiform 
discharges generated by EKP (Fig. 5B). Other ASDs were not active. For representative LFP recordings of 
EKP-treated larvae in combination with (or without) ASD pretreatment see Fig. S3.
For the neuroluminescent assay the cumulative amount of photons emitted during the 30-min EKP expo-
sure period was quantified for VHC- and ASD-pretreated animals. ASDs were also tested at their MTC except 
for ETS and TGB which were evaluated at lower concentrations of 250 µM and 50 µM, respectively, due to toxic 
side-effects when co-incubated with CLZN-h. As shown in Fig. 5C, EKP-induced neuronal activity was signifi-
cantly diminished in PHT, RGB, ZSM, PER and TPM pre-treated animals.
Homology modelling and ligand docking. The absence of 14 amino acids in the crystal structure for 
the human GAD65 (2OKK) is indicative of a flexible region in the protein. Therefore, the presence of a flexible 
loop was hypothesized by analyzing the superposition between the homology models and the human crystal 
structures. Final dimeric models after refinement of this flexible loop are shown in Fig. 6A and C for gad67 and 
gad65 respectively, demonstrating that the two subunits are intertwined as a result of an induced fit of the flexible 
loop (colored in pink).
For both final gad67 and gad65 dimeric models, the glutamate binding mode was compared to the ones of 
docked KPA and EKP. The binding affinity and the Ki values calculated by Autodock are reported in Table 1 for 
each of the complexes. Since values for the monomers are not within the range that is in agreement with observed 
Figure 2. Behavioral profile of zebrafish larvae exposed to EKP. (A) Locomotor behavior of 7 dpf larvae treated 
with EKP (200 μM–800 μM) as compared to VHC-treated larvae. The data on the Y-axis refer to the average 
total movement of larvae per 5-minute (min) intervals. Results shown were pooled from four independent 
experiments with 12 larvae per experiment that were individually analyzed. Error bars represent s.d. (B) Phase 
2 seizure-related behavior observed in zebrafish exposed to EKP. Zebrafish larvae at 7 dpf were incubated with 
medium containing 200 μM–800 μM EKP for 30 min. The total number of larvae displaying phase 2 behavior 
was added up per minute interval. Each group represents a total of 12 larvae. (C) Kaplan-Meier cumulative 
survival curve of 7 dpf larvae during exposure to 200 µM–800 μM EKP or VHC (n = 36 for each group).
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in vivo effects, the obtained Ki values confirm the hypothesis of dimerization. A close up of studied inhibitors and 
the native glutamate in the active site of gad67 and gad65 is shown in Fig. 6B and E respectively, demonstrating 
that the spatial binding mode of both ligands overlaps with the native binding of glutamate. It also indicates the 
importance of the carboxyl group (or ester group in EKP) that is engaged in close interactions with GLN84.B, 
LEU85.B, SER86.B and ARG457.B in both enzymes. The fact that EKP binds with slightly less affinity, could be 
explained by the presence of an ester group whereas KPA has a carboxyl group that has more favorable electro-
static interactions with ARG457.B.
The importance of the dynamic loop (ALA307.A – PHE354.A) is highlighted by the extra interactions with 
both inhibitors as shown in Fig. 6C and F. At position 325.A the glycine is in gad67 replaced by cysteine gad65 
which displaces TYR356.A out of the active site in gad65. In addition, the active site contains a PHE184.B in 
gad65 instead of a more polar TYR184.B in gad67. Both of these relatively small differences account for more 
extensive hydrophobic interactions to occur in the active site of gad65 compared to gad67, that are slightly with-
drawing ligands from the crucial ARG457.A towards the hydrophobic part of the active site. In gad67 however, a 
spatially more favorable interaction is observed between the carboxyl moiety of ligands and ARG457.B, explain-
ing the slightly improved Ki for ligands in the gad67 isozyme compared to gad65.
Figure 3. EKP induces abnormal electrographic activities in the optic tectum and c-fos expression in brain 
of 7 dpf larvae. (A) Fragments of representative recordings from 7 dpf larva treated with VHC (A1) or 
15 min after application EKP (400 µM) (A2). Bottom trace (A3) shows a high-resolution magnification of the 
epileptiform events indicated above. (B) Number of epileptiform events in VHC and EKP treated larvae: VHC 
0.4857 ± 0.1804 vs EKP 55.76 ± 6.872 events/10 min recording. The number of recordings analyzed were: VHC 
(n = 35) and EKP (n = 58). Statistical analysis was performed using Student’s unpaired t-test. Values that were 
significantly different compared to VHC were indicated with ****p ≤ 0.0001. Error bars on all graphs represent 
s.d. (C) EKP-induced seizure upregulated c-fos expression in 7 dpf zebrafish larvae as assessed by qPCR (PTZ 
was used as positive control). c-fos expression is normalized to the housekeeping gene ef1α and β-actin 1. The 
data were analyzed using the ΔΔCq method and reported as mean ± s.e.m. of three experiments performed in 
triplicate.
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Discussion
In this study we provide evidence that EKP acts as a strong inducer of epileptiform activities in zebrafish larvae. 
Compared with AG13, EKP induced hyperactivity at a 100-fold lower concentration. In addition, hyperactivity 
occurred more synchronously and with a fast onset. We also found a clear increase of epileptiform discharges 
in EKP-treated larvae that matches well with the outcome of the locomotor assay and the c-fos expression study.
Moreover, also a neuroluminescent approach was used to investigate the proconvulsant effect of EKP. The 
genetically modified larvae used to this end specifically express a Ca2+ sensor that generates bioluminescent 
signals upon strong neural activation38. We found that EKP exerted a dramatic effect on neuronal brain activity, 
as seen from the emission of large waves of neuroluminescence that could easily be measured and quantified.
From the experimental work it also became clear that the neuroluminescence-dependent assay offers several 
advantages over LFP recordings: (i) the larvae can freely move and hence there is no need to embed or paralyze 
them, (ii) recordings do not depend on the correct positioning of a needle that causes inherently interexperimen-
tal inconsistencies, (iii) brain activity is assessed as a whole as opposed to electrode recordings that monitor only 
a very small part of the brain, and (iv) long-term recordings are possible, which might be essential for zebrafish 
seizure models with infrequent and conditional seizure activities. Furthermore, the method is also compatible 
with future simultaneous live and video-based recordings of movement and epileptiform activities as an equiva-
lent to clinical video-EEG monitoring.
Protein docking revealed that both KPA and EKP exhibited similar GAD binding affinity as glutamate. The 
interaction of the carboxyl (in KPA and glutamate) or ester group (in EKP) of these ligands with an arginine res-
idue in the active site contributed strongly to protein binding. The hypothesis that dimers are formed and that a 
dynamic loop is present correlated with the observed difference in inhibition constants between the monomeric 
and dimeric models. Two of the mutations in the active site (Phe184 vs Tyr184 and Gly325 vs Ser325) could 
explain the small difference in affinity of the inhibitors towards gad65 and gad67, however altogether it appears 
Figure 4. Neuroluminescence recording of Tg(elavl3:GA) zebrafish exposed to EKP. (A) Bright field (upper) 
and fluorescence (lower) micrographs of 7 dpf Tg(elavl3:GA) larva (scale bar: 0.20 mm) (B) Photon emission of 
7 dpf larvae exposed to VHC (black line) or EKP (400 µM) (red line), after a 20 h incubation to CLZN-h (40 µM) 
exposure during a 30-min recording period. The total photon emission (y-axis) is counted per 5-second (sec) 
interval (x-axis). Results are expressed as mean ± s.d. of 18 independent experiments. For each experiment a 
group of three larvae was used.
www.nature.com/scientificreports/
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that the proconvulsant activity observed in the different assays can be attributed to direct inhibition of both 
enzymes.
Further, we evaluated the efficiency of commonly used ASDs representing multiple mechanism of actions 
(MOA) to reduce the epileptiform zebrafish phenotype induced by EKP as assessed by the three different assay 
tools. To make a straightforward comparison, a heat map was generated that provides a visual summary of the 
EKP-related responses upon treatment with different ASDs. Total number of movements, epileptic events and 
photons emitted after ASDs pretreatment were normalized against the EKP-treated group (Fig. 5D). Overall, 
EKP-treated larvae responded poorly to most of the tested ASDs suggesting that EKP-induced seizures in zebraf-
ish are treatment-resistant. Despite the fact that EKP is a potent inhibitor of GAD leading to GABA depletion 
Figure 5. Quantitative analysis and comparison of locomotor activity, electrographic activity and 
neuroluminescence of larvae treated with EKP in combination with/without ASDs. (A) Larval locomotor 
activity within a 30-min recording normalized to EKP control (set at 100%). Results are shown as mean ± s.e.m. 
of 12 experiments (recordings of individual larvae) performed in triplicate. (B) Number of epileptic events 
within a 10-min recording (mean ± s.d.). Number of recordings analyzed were: VHC (n = 35), EKP (n = 58), 
LMT (n = 13), CBZ (n = 11), PMD (n = 14), ETS (n = 18), LVT (n = 14), TGB (n = 13), PHT (n = 14), RGB 
(n = 16), VPA (n = 14), OXC (n = 13), ZSM (n = 15), PER (n = 14), TPM (n = 16) and ASP (n = 12). (C) 
Number of photons emitted within a 30-min recording. Results are expressed as mean ± s.d. of at least 5 
independent experiments. For each experiment a group of three larvae was used. All results (A, B, C) were 
analyzed using one-way ANOVA. Significant differences compared to EKP group are marked with *, **, ***, 
**** (p ≤ 0.05, p ≤ 0.01, p ≤ 0.001 and p ≤ 0.0001 respectively). (D) Heat map comparison of larval responses 
against EKP after different ASD treatment as examined by locomotor tracking, electrographic activity recording 
and neuroluminescence measurements. Data from ASD-treated larvae were normalized against results of the 
EKP-treated groups.
www.nature.com/scientificreports/
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no correlation could be found between the anti-seizure response and a specific MOA of different ASDs. This 
contrasts with a number of widely used seizure models utilizing GABAA inhibiting compounds (e.g. PTZ, 
picrotoxin or bicuculline) which are most sensitive to GABAergic ASDs (e.g. barbiturates or benzodiazepines). 
Consequently, our observations could indicate that the EKP model does not show bias for any particular MOA of 
existing ASDs and may potentially lead to the discovery of mechanistically novel anti-seizure compounds.
Nevertheless, we observed that three ASDs, namely PER, ZSM and TPM, exhibited consistent reduction 
in epileptiform events. Of note, TPM as well as PHT were only slightly active in the locomotor activity assay. 
Additionally, PHT and RGB were found to be active in the neuroluminescence assay, but did not show significant 
effects in LFP recordings. In fact, certain ASDs may have preferential effects against secondary generalization 
and spread of seizures, which had been observed in rodent models like the amygdala kindling39. The observed 
difference may also stem from the fact that neuroluminescence monitor whole brain activity, whereas LFP meas-
urements detect signals generated from a small population of optic tectal neurons. As a result, LFP-based assays 
tend to be less sensitive in detecting signals occurring in brain locations that are distant from the recording spot.
Thus, neuroluminescence offers a window of opportunity to identify compounds that would have passed 
unnoticed by standard electrophysiological methods. Furthermore, neuroluminescence assay may be able 
to detect seizure-like activity that is not associated with clear-cut convulsive behaviors in zebrafish, e.g. 
non-convulsive seizures. Since our study represents the first comprehensive evaluation of ASDs efficacy in a 
convulsant-induced seizure zebrafish model using a neuroluminescence readout, the model will be further tested 
with the criteria of reliability and usefulness using other convulsant compounds. This will provide more infor-
mation about its general applicability and detection rates of false positive and negative compounds. In addition, 
further developments are possible as it feasible to combine the synchronous recording of bioluminescent signals 
and locomotor behavior of the freely moving larvae38. Moreover, zebrafish expressing genetically encoded cal-
cium indicators (GCaMPs) have successfully been used to monitor in real-time whole brain 3D neuronal activity 
Figure 6. Dimeric models after refinement of the flexible loop (pink) for gad67 (A) and gad65 (D). Close-up on 
the active site with superimposed EKP (cyan), KPA (purple) and glutamate (blue) for gad67 (B) and gad65 (E). 
Important amino acids for interaction with the carboxyl-group are labeled. Zoom on the interactions of ligands 
with residues in the flexible loop in for gad67 (C) and gad65 (F).
Ki
gad67 (µM) gad65 (µM)
Monomer Dimer Monomer Dimer
GLU 881.4 29.1 871.9 30.1
EKP 1110.6 45.8 1163.0 55.2
KPA 749.3 35.6 820.2 41.4
BA gad67 (kcal/mol) gad65 (kcal/mol)
GLU −4.18 −6.20 −4.18 −6.18
EKP −4.04 −5.93 −4.01 −5.82
KPA −4.28 −6.08 −4.22 −5.99
Table 1. Binding affinity (BA) in Kcal/mol and the Ki values in µM resulting from docking of GLU (glutamate), 
EKP and KPA in both monomeric and dimeric models of enzymes gad67 and gad65 of Danio rerio. EKP (values 
in bold) shows similar results in comparison to GLU and KPA.
www.nature.com/scientificreports/
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in immobilized zebrafish larvae40. When compared to the bioluminescent approach that does not provide any 
spatial information on the emitted light signal, this fluorescence-based method would possibly allow to local-
ize the EKP-induced seizures and discern whether they are focal or not, and investigate further into detail the 
anti-seizure activity of a few selected compounds of interest.
Epilepsy is a very heterogeneous disease and acute preclinical seizure models typically do not mimic any par-
ticular epilepsy syndrome, but rather reflect certain seizure types (e.g. MES, PTZ or 6 Hz). Yet, it can be argued 
that animal models of seizures have shown generally high predictive validity for a therapeutic drug response 
in patients. Thus, any seizure model does not need to be a perfect replication of the clinical condition, but it is 
important that the validation provided for a given model is “fit for purpose”41.
We have demonstrated for the first time a robust convulsive effect of EKP, a potent GAD inhibitor, in 7 dpf 
zebrafish larvae. EKP increased locomotor activity, induced epileptiform events and a corresponding increase in 
neuroluminescence, and increased synaptic activity-regulated c-fos expression.
EKP-induced seizures were similar to those caused by AG, but with much shortened seizure latency and a 
more synchronized seizure onset. However, it remains to be established if this model, like many other acute sei-
zure models in both zebrafish and rodents, represent any particular epilepsy syndrome despite strong evidence 
that GAD has been implicated in pathophysiology of epilepsy. Our findings support the suggestion that the EKP 
zebrafish model is characterized by poor response to several existing ASDs and may become a useful addition to 
the armamentarium of animal models of drug resistant seizures. In fact, no single model has been validated for use 
to identify potential compounds effective against drug resistant seizures. Consequently, it is suggested that a bat-
tery of such models should be employed, thus enhancing the sensitivity to discover novel, highly effective ASDs42.
In conclusion, the zebrafish EKP model can therefore be used for screening of drug-like hits in an early step of 
the discovery of mechanistically novel ASD candidates. Furthermore, it is anticipated that by providing quantifia-
ble whole brain-related Ca2+ signals in freely moving transgenic animals, the neuroluminescence technique might 
turn out to be of particular interest for future drug discovery strategies in the field of epilepsy and epileptogenesis.
Materials and Methods
Animals and maintenance. Adult zebrafish (Danio rerio) were maintained in a UV-sterilized rack recir-
culating system equipped with a mechanical and biological filtration unit and kept under a 14/10 hour light/dark 
cycle at the temperature of 27–28 °C and pH of 6.8–7.5. Water quality was monitored for pH, temperature, con-
ductivity, ammonia, nitrite (SL1000 Portable Parallel Analyzer, Hach Instruments, USA) and nitrate levels (Tetra, 
Melle, Germany). Zebrafish were fed three times per day with flake food (TetraMin, Tetra, Germany) and Artemia 
(brine shrimp). Embryos were obtained via natural spawning, then sorted and kept in petri dishes (92 × 16 mm, 
Sarstedt, Nümbrecht, Germany) at 28 °C in a Peltier-cooled incubator (IPP 260, Memmert, Schwabach, Germany) 
in embryo medium (Danieau’s solution: 1.5 mM HEPES, 17.4 mM NaCl, 0.21 mM KCl, 0.12 mM MgSO4, and 
0.18 mM Ca(NO3)2 and 0.6 μM methylene blue). For the generation of the Tg(elavl3:eGFP-apoAequorin) line, the 
mitfa−/− (nacre) strain was used. This strain lacks body pigmentation and hence the fluorescent/neurolumines-
cent signal is easier to observe. For all other experiments 1–7 dpf larvae of the AB strain were used.
All zebrafish experiments were approved by the Ethics Committee of the University of Leuven (Ethische 
Commissie van de KU Leuven, approval number ECD P101/2010) and by the Belgian Federal Department 
of Public Health, Food Safety & Environment (Federale Overheidsdienst Volksgezondheid, Veiligheid van de 
Voedselketen en Leefmileu, approval number LA1210199). All procedures were carried out according to the 
Declaration of Helsinki and conducted according to the guidelines of the European Community Council directive 
86/609/EEC.
Compound treatment. Ethyl ketopentenoate (EKP) was synthetized according to a procedure described 
in supplementary materials. Pentylenetetrazol (PTZ), lamotrigine (LMT), carbamazepine (CBZ), primidone 
(PMD), ethosuximide (ETS), levetiracetam (LVT), valproate (VPA), oxcarbazepine (OXC), zonisamide (ZSM), 
topiramate (TPM) and aspirin (ASP) were purchased from Sigma. Other compounds used were: phenytoin (PHT) 
(Acros), tiagabine (TGB) (Chemos), perampanel (PER) (Eisai), retigabine (RGB) (Valeant Pharmaceuticals/
GlaxoSmithKline) and coelenterazine-h (CLZN-h) (NanoLight® Technologies). All compounds were dissolved 
in dimethyl sulfoxide (DMSO) and kept as a stock at −20 °C or −80 °C. Stock solutions were further diluted in 
embryo medium for locomotor activity assay and local field potential recordings, or E3 medium (5 mM NaCl, 
0.17 mM KCl, 0.33 mM CaCl2 and 0.33 mM MgSO4) for neuroluminescence recording to achieve a final DMSO 
concentration of 1% w/v. As vehicle control (VHC) 1% w/v DMSO in embryo or E3 medium was used.
Generation of Tg(elavl3:eGFP-apoAequorin) line. A transgenic fish line Tg(elavl3:eGFP-apoAequorin) 
was generated with the pan-neuronal elavl3 promoter that drives the expression of a fusion of eGFP and 
apoAequorin. Briefly, the elavl3 promoter (a gift from Dr. Florian Engert, Harvard, USA) and the coding 
sequence for the eGFP-apoAequorin fusion protein43 (a gift from Dr. Ludovic Tricoire, Université Pierre/Marie 
Curie, France) were cloned into a gateway expression vector flanked with tol2 recognition sites. To generate sta-
ble transgenic zebrafish, 20 pg of the elavl3:eGFP-apoAequorin plasmid DNA was co-injected with 100 pg tol2 
transposase mRNA into the cytoplasm of single cell stage fertilized nacre zebrafish embryos. Injected embryos 
were screened for eGFP expression at 2–5 dpf. eGFP positive individuals (F0) were grown to adulthood and 
out-crossed with nacre zebrafish. All the experiments with were performed with progeny (F3) from intercrossing 
stable F2 transgenics.
Analysis of gad1b and gad2 expression using qPCR. A. RNA extraction and cDNA synthesis: Total 
RNA was extracted from 12 embryos on 1 to 7 dpf using TRIzol (Life Technologies) according to manufacturer’s 
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instructions. Following DNase (Roche) treatment, RNA was quantified by NanoPhotometer P330 (Implen). 
cDNA was synthesized from 1 μg of total RNA using random primers and SuperScript III reverse transcriptase 
(Invitrogen) according to the manufacturer’s instructions and further diluted 1:20.
B. qPCR analysis: For analysis of gad1b and gad2 mRNA expression, 4 μl of each cDNA was amplified with 
Bio-Rad 20x PrimePCR assays (gad1b assay ID: qDreCID0019786; gad2 assay ID: qDreCID0014650) and 2x 
SsoAdvanced Universal SYBR Green Supermix (Bio-Rad). H2O was used as none template control (NTC). qPCR 
reactions were performed with HardShell® Low-Profile Thin-Wall 96-Well Skirted PCR Plates (Bio-Rad) on 
CFX96 Touch Real-Time PCR Detection System (Bio-Rad) under cycling conditions according to the manufac-
turer’s protocol. Data generated by real-time PCR were compiled using CFX Manager Software (Bio-Rad). The 
gad1b and gad2 transcripts were normalized against ef1α and 18 s (primers: Table S1). The relative expression 
levels were quantified using the comparative Cq method (ΔΔCq). Amplification specificity was monitored by 
examining the final melting curve.
Validation of larval zebrafish EKP seizure model. Locomotion activity. Larvae (6 dpf) in 100 µl VHC 
were arrayed individually in a 96-well plate (tissue culture plate, flat bottom, Falcon, USA) and kept for 18 h in the 
dark at 28 °C. Prior to tracking the following day (7 dpf) 100 μl of VHC or EKP stock solution was added to each 
well to obtain a range of EKP concentrations (200 μM-800 μM). The plates were placed in an automated video 
tracking device (ZebraBoxTM apparatus; Viewpoint, Lyon, France) and 5 min later the locomotor behavior of the 
larvae was monitored for 2 h in the dark at 28 °C. Locomotor activity was quantified using ZebraLab™ software 
(Viewpoint, Lyon, France) and expressed in “actinteg” units per 5-min interval. The actinteg value is defined as 
the sum of all image pixel changes detected during the time window.
Video recordings of individual wells were used between 0–30 min to assess the cumulative number of larvae 
exposed to the different EKP concentrations that had exhibited phase 2 seizures. These seizures are defined as 
rapid corkscrew-like accompanied with entire body jerking and twitching, which are easily distinguished from 
other behavioral abnormalities (for description of phase 1 and 3 seizures, see results).
Survival rate. Larvae (7 dpf) were arrayed individually in a 96-well plate, exposed to EKP (200 μM-800 μM) or 
VHC (control) and immediately scored under a stereomicroscope for lethality every 5 min for 1 h.
Local field potential (LFP) recordings. Larvae (6 dpf) in 100 µl VHC were arrayed individually in a 96-well plate 
and kept for 18 h in the dark at 28 °C. An equal volume of 800 μM EKP (2x solution) or VHC (control) was added 
to each well and hence larvae were incubated with 400 μM EKP for 15 min. Next, the treated larva was embedded 
ventral side down in 2% low melting point agarose bathed in artificial cerebrospinal fluid (ACSF, 124 mM NaCl, 
2 mM KCl, 2 mM MgSO4, 2 mM CaCl2, 1.25 mM KH2PO4, 26 mM NaHCO3, and 10 mM glucose). A blunt glass 
electrode (soda lime glass, Hilgenberg, Germany) was pulled with DMZ Universal Puller (Zeitz, Germany) to an 
opening of 15–20 microns, filled with ACSF and placed on the skin above the optic tectum. The recordings were 
performed using WinEDR (John Dempster, University of Strathclyde, UK). Differential signal was band pass 
filtered at 0.3–300 Hz and digitized at 2 kHz via a PCI-6251 interface (National Instruments, UK). LFP recordings 
started each time exactly 2 min after the removal of the larva from the EKP solution (or VHC) and were continued 
for 10 min at room temperature (24 °C).
EKP-induced events were considered as epileptiform activity when their signal exceeded three times the base-
line and lasted for minimum 100 msec, as described previously44. Electrophysiological recordings were analyzed 
in a blinded way using Clampfit 10.2 software (Molecular Devices, USA).
Analysis of c-fos expression in larval heads using qPCR. To measure the seizure-related changes in c-fos mRNA 
expression in the CNS, 12 larvae (7 dpf) were treated with either 20 mM PTZ, 400 μM EKP or VHC for 15 min 
and then rapidly decapitated. The heads were immediately processed for RNA isolation followed by cDNA syn-
thesis as described for gad1b and gad2. qPCR analysis of c-fos mRNA expression using Bio-Rad 20x PrimePCR 
assays (c-fos assay ID: qDreCED0015103) was performed as described for gad1b and gad2, and normalized to the 
housekeeping gene ef1α and β-actin 1 (primers, Table S1).
Neuroluminescence recording. Tg(elavl3:eGFP-apoAequorin) zebrafish larvae were visually screened for even 
GFP expression at 3 dpf. Selected larvae were incubated with VHC in 40 µM CLZN-h for 18–24 h in the dark at 
28 °C38. Excess of CLZN-h was removed by washing larvae repeatedly in E3 medium afterwards. A group of 3 lar-
vae was then transferred into a light-tight thermostated perfusion chamber (27–28 °C) containing either VHC or 
400 µM EKP. The recordings started each time exactly 5 min after EKP exposure and were continued for 30 min. 
Photons emitted were detected by a photon-counting tube (Type H3460–04, Hamamatsu Photonics, Japan) that 
was positioned about 2 cm above the larvae. Light impulses were discriminated, prescaled and counted with 
a PC-based 32-bit counter/timer board (PCI-6601, National Instruments Corporation, Austin, TX, USA). The 
number of impulses occurring during a 5-sec time interval was monitored with custom-built software. Analysis 
of the bioluminescence recordings was done in a blinded way.
Pharmacology of larval zebrafish EKP seizure model. A schematic comparison of timelines of the 
different experiments is depicted in Fig. 7.
Maximum tolerated concentration (MTC). Before performing pharmacological experiments, MTC of each ASD 
was determined as described previously11.
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Effect of ASDs on EKP-induced locomotion activity. Larvae (6 dpf) were exposed to VHC or ASDs at their respec-
tive MTC for 18 h in the dark at 28 °C. Then, the larvae were treated with 400 µM EKP (or VHC) and the locomo-
tion activity was monitored for 30 min (after 5 min of habituation) as described earlier. The average amount of 
movement per 5-min intervals was measured, quantified and normalized to the EKP control group for the entire 
30-min tracking session or per 5-min interval.
Effect of ASDs on EKP-induced epileptiform discharges. Larvae (6 dpf) were exposed to VHC or ASDs at their 
respective MTC for 18 h in the dark at 28 °C. Then, the larvae were treated with 400 µM EKP (or VHC), embedded 
in agarose, and the LFP recordings were performed as described earlier.
Effect of ASDs on EKP-induced neuroluminescent events. eGFP-positive Tg(elavl3:GA) zebrafish larvae (6 dpf) 
were exposed to VHC or ASDs at their respective MTC (as determined in E3-CLZN solution) and 40 µM-h CLZN 
for 18 h in the dark at 28 °C. Larvae were then washed repeatedly in E3 medium and groups of three larvae were 
transferred into a light-tight thermostated perfusion chamber (27–28 °C) containing either VHC or 400 µM EKP. 
Recordings were performed as described earlier.
Protein ligand docking. Using i-Tasser45, homology models for gad65 and gad67 were created for Uniprot 
sequences F1R9E8 and Q7ZUS3 and pdb structures 2OKK and 2OKJ as templates respectively46. Cα traces 
in dimer models are constructed with COTH47 starting from 2OKJ using 484 residues in each of the subunits 
(first 97 residues in gad65 and 101 in gad67 are omitted). For the ease of comparison, residue numbering in 
both models starts at 1. The SABBAC server48 and AMBER software49 were used for backbone reconstruction 
and final energy minimization respectively. Loop remodeling was performed with the loop refinement tool in 
USCF Chimera50. Finally, a short molecular dynamics simulation of 20 nanoseconds (nsec) was performed. 
Ramachandran plots were hereafter generated to verify the quality of the homology model51 (Fig. S1).
Flexible docking was performed using Autodock52 in one of the active sites of the dimeric homology models. 
A grid unit of 0.375 A was used with a 3-dimensional box having sides of 40 units. The grid box center for gad67 
and gad65 was chosen to be (11.693, 17.627, −20.110) and (−6.749, 16.877, 132.140) respectively. Residues 108.A, 
326.A, 327.A, 329.A, 347.A, 83.B, 84.B, 85.B, 86.B, 183.B, 184.B, 240.B, 297.B, 457.B were selected to be flexible. 
The Genetic Algorithm output was chosen in combination with the generation of 100 docked structures. The 
conformations located in the top cluster (with an rmsd-value of zero) were visually analyzed in USCF Chimera50. 
Within each gad, the conformations were superimposed to visualize differences in binding mode. Analysis of 
hydrogen bonds and hydrophobic interactions was performed by USCF Chimera and LigPlot+53. N6-(pyridoxal 
phosphate) lysine was parametrized based on empirical data for all docking and molecular dynamics simulations.
Data analysis. Statistical analysis was performed using one-way or two-way ANOVA followed by Dunnett’s 
multiple comparison test with GraphPad Prism Version 7.0c (San Diego, CA).
Data availability. All data supporting this work are included in this manuscript.
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